Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. 1997

O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
Department of Cardiothoracic Surgery, Ullevål Hospital, University of Oslo, Norway.

BACKGROUND The inflammatory response induced by cardiopulmonary bypass can result in severe organ dysfunction in some patients. This postperfusion response is caused mainly by contact between blood and the foreign surface of the cardiopulmonary bypass equipment and includes adhesion of leukocytes to vascular endothelium, which precedes a series of events that mediate inflammatory damage to tissues. METHODS Low-risk patients accepted for coronary artery bypass grafting were randomized to operation with the cardiopulmonary bypass surface either completely heparin coated (Duraflo II) or uncoated. There were 12 patients in each group. Blood plasma sampled during cardiopulmonary bypass was analyzed for complement activation (C3bc and terminal SC5b-9 complement complex) and neutrophil activation (lactoferrin and myeloperoxidase). In addition, neutrophils, monocytes, and platelets were counted, and the expression of surface markers on the neutrophils and monocytes (complement receptor [CR] 1, CR3, CR4, and L-selectin) and on the platelets (P-selectin and CD41) was quantified with flow cytometry. RESULTS Clinical and surgical results were similar in both groups. In the group with the heparin-coated surface, the formation of the terminal SC5b-9 complement complex was significantly reduced, and the counts of circulating leukocytes and platelets were significantly less reduced initially but were higher at the end of cardiopulmonary bypass compared with baseline. Also, the expression of CR1, CR3, and CR4 was significantly less upregulated and the L-selectin, significantly less downregulated on monocytes and neutrophils. CONCLUSIONS We conclude that heparin coating reduces complement activation and attenuates the leukocyte integrin and selectin response that occurs when uncoated circuits are used.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell

Related Publications

O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
August 1994, The Annals of thoracic surgery,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
July 1996, Artificial organs,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
December 1995, The Annals of thoracic surgery,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
January 1996, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
September 1999, Panminerva medica,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
February 1990, Artificial organs,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
September 1995, The Journal of thoracic and cardiovascular surgery,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
April 1999, The Journal of thoracic and cardiovascular surgery,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
July 1988, Annals of surgery,
O Moen, and K Høgåsen, and E Fosse, and E Dregelid, and V Brockmeier, and P Venge, and M Harboe, and T E Mollnes
March 1996, The Annals of thoracic surgery,
Copied contents to your clipboard!